Gamma-Mangostin (0.5, 1, 2 mg/kg; Oral gavage (p.o.); 14 days) significantly reduces fasting blood glucose, cholesterol, serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), and ameliorates damaged hepatocytes, primarily swelling, hydropic changes, and necrotic cells in the streptozotocin (STZ) (HY-13753) (30 mg/kg) induced diabetic BALB/C mouse model[3].
Gamma-Mangostin (1, 2, 4 mg/kg; Oral gavage (p.o.); 14 days) significantly reduces blood urea nitrogen (BUN) and creatinine in plasma, and ameliorates the damage to renal proximal tubular cells in BALB/C mice with streptozotocin (STZ) (HY-13753) (30 mg/kg) induced diabetes[4].
Gamma-Mangostin (0.1, 0.2, 0.4 mg; Oral gavage (p.o.); 4 weeks) can reduce fasting blood glucose levels and oral glucose tolerance tests in diabetic ICR mice[5].
| Animal Model: | STZ (HY-13753) (30 mg/kg)-induced BALB/C diabetic mouse model[3] |
| Dosage: | 0.5 mg/kg, 1 mg/kg, 2 mg/kg |
| Administration: | Oral gavage (p.o.); 14 days |
| Result: | Significantly reduced fasting blood glucose, cholesterol, serum glutamic oxaloacetic transaminase (SGOT), and serum glutamate-pyruvate transaminase (SGPT) in diabetic mice.
Improved damaged liver cells, primarily those exhibiting swelling, water accumulation, and cell necrosis.
|
